Enhanced plasma NDEV levels of total tau, tau phosphorylated at threonine 181 (P-T181-tau), and tau phosphorylated at serine 396 (P-S396-tau) have also been reported in AD cases with respect to controls [10–12, 17, 21], but some authors failed to show such group differences for several of these tau parameters [11, 22, 23]. The gene discussed is MAPT; the disease is Alzheimer disease.